ProMIS Neurosciences, Inc. (NASDAQ: PMN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $6.00 price target on the stock.
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights [Yahoo! Finance]
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting [Yahoo! Finance]